Stereochemistry | ABSOLUTE |
Molecular Formula | C7H14N2O6S |
Molecular Weight | 254.261 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCC(=O)NCCS(O)(=O)=O)C(O)=O
InChI
InChIKey=WGXUDTHMEITUBO-YFKPBYRVSA-N
InChI=1S/C7H14N2O6S/c8-5(7(11)12)1-2-6(10)9-3-4-16(13,14)15/h5H,1-4,8H2,(H,9,10)(H,11,12)(H,13,14,15)/t5-/m0/s1
Molecular Formula | C7H14N2O6S |
Molecular Weight | 254.261 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Glutaurine is formed from the amino group of taurine with the gamma-carboxy group of L-glutamic acid. It was originally discovered in the parathyroid. Evidence has been found suggesting that glutaurine plays a role in peripheral thyroid hormonal regulation. Glutaurine increases triiodothyronine (T3) levels, but does not alter thyroxine (T4) levels. Glutaurine was also shown to prevent electroconvulsive shock-induced amnesia by counteracting the shock effect on the memory consolidation phase. Other roles that have been suggested for glutaurine include roles as a mouse metabolite, a mammalian metabolite, a human metabolite, an anticonvulsant, an anxiolytic drug and a hormone.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|